MS and Demyelinating Disorders

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 24, 2023.

Between pretreatment naïve patients and those previously on disease-modifying therapies, treatment with cladribine resulted in stable scores on Symbols Digit Modalities Test and other cognitive assessments.

The multiple sclerosis fellow at Michigan Institute for Neurologic Disorders provided perspective on the clinical utility and advantages of a multi-protein test that assesses multiple sclerosis disease activity. [WATCH TIME: 3 minutes]

Secondary findings from a phase 3 study demonstrate a significant decrease in new T1 enhancing lesions and new enlarging hyperintense T2 lesions in patients with multiple sclerosis undergoing glatiramer acetate depot treatment.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Darin Okuda, MD. [LISTEN TIME: 21 minutes]

Study results suggest that selected interventions should be based on phenotypic differences and treatment goals.

Non-Hispanic Black and Hispanic or Latino individuals on ocrelizumab did not demonstrate significantly greater risk on 24-week confirmed disability progression relative to non-Hispanic Whites.

Majority of patients with relapsing multiple sclerosis demonstrated achieving and maintaining no evidence disease activity after being treated with ublituximab.

The program committee vice-chair of ACTRIMS discussed the continued efforts to understand inflammation and neurodegeneration of multiple sclerosis. [WATCH TIME: 3 minutes]

The neurologist at Mayo Clinic in Jacksonville Florida talked about the significance of the ExTINGUISH trial, regarding care for patients with autoimmune encephalitis. [WATCH TIME: 4 minutes]

Gregory Day, MD, MSc, MSCI, FAAN, a neurologist at Mayo Clinic in Jacksonville Florida, talked about the current state of treating autoimmune encephalitis and the significance of the ExTINGUISH trial.

In honor of World Encephalitis Day, held February 22, 2023, get caught up on some of the latest news in autoimmune encephalitis as the NeurologyLive® team shares some of our data updates and expert insights.

The associate professor at Harvard Medical School spoke with NeurologyLive® about the differences between patients with multiple sclerosis and those with NMOSD. [WATCH TIME: 3 minutes]

The program committee vice-chair of ACTRIMS provided perspective on the upcoming forum, including the notable sessions, themes, and presentations the clinical community should be aware of. [WATCH TIME: 7 minutes]

Patients who switched from a previous disease-modifying therapy to teriflunomide saw a decrease in annualized relapse rate and stability with Expanded Disability Status Scale scores regardless of subgroups.

Daniel Ontaneda, MD, program committee vice-chair of ACTRIMS, provided insight on the notable sessions and themes clinicians should pay attention to at this year’s forum, which takes place February 23-25, in San Diego, California.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending February 18, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 17, 2023.

On diffusion tremor imaging, CMN-Au8 outperformed placebo on domains of fractional anisotropy, radial diffusivity, and mean diffusivity, across all 9 prespecified brain regions and brain white matter.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 10, 2023.

Catch up on any of the neurology news headlines you may have missed over the course of January 2023, compiled all into one place by the NeurologyLive® team.

The biosimilar form of natalizumab demonstrated similarities to the FDA-approved form in the primary efficacy end point of cumulative number of new active lesions over 24 weeks.

The trial was originally placed on hold because of reported cases of drug-induced liver injury in patients who received the study drug, potentially caused by a preexisting factors related to hepatic dysfunction.